Deferasirox pharmacokinetic parameters
| . | Vd/F(L) . | Vd/F(L/kg) . | CL/F(L/h) . | T1/2,Elim(h) . | AUC(μM.h) . |
|---|---|---|---|---|---|
| Responders, n = 5 | 6.57 ± 2.67 | 0.13 ± 0.05 | 0.61 ± 0.22 | 7.83 ± 2.95 | 1123.11 ± 63.4 |
| Inadequate responders, n = 10 | 10.33 ± 7.42 | 0.32 ± 0.25 | 1.30 ± 1.18 | 6.08 ± 2.01 | 479.59 ± 259.42 |
| P | .178 | .062 | .104 | .275 | < .001 |
| . | Vd/F(L) . | Vd/F(L/kg) . | CL/F(L/h) . | T1/2,Elim(h) . | AUC(μM.h) . |
|---|---|---|---|---|---|
| Responders, n = 5 | 6.57 ± 2.67 | 0.13 ± 0.05 | 0.61 ± 0.22 | 7.83 ± 2.95 | 1123.11 ± 63.4 |
| Inadequate responders, n = 10 | 10.33 ± 7.42 | 0.32 ± 0.25 | 1.30 ± 1.18 | 6.08 ± 2.01 | 479.59 ± 259.42 |
| P | .178 | .062 | .104 | .275 | < .001 |
Mean ± SD of responders versus inadequate responders with corresponding P based on the unpaired t test.
Vd indicates volume of distribution; F, bioavailability; CL, clearance; t, elimination half-life; and AUC, exposure, measured as area under the curve.